drugset
drugset / Trial / NCT05284851

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

NCT05284851 ↗

Phase 2 Unknown 2520 enrolled Changchun BCHT Biotechnology Co. He Bei province Center for Disease control and prevention · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase two trail is to evaluate the immunogenicity of LAVI (non freeze- dried). The secondary objective is to evaluate the safety of LAVI (non freeze- dried).

Timeline

Start
2022-04-01
Primary completion
2022-05-01
Completion
2022-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator FluMist Vaccine — —

Indications

No indication recorded.